Biotech firm develops drug to slow biological aging in dogs

Agencies. Companies worldwide are investing billions of dollars in the hope of creating drugs that slow down aging.

However, everyone is facing challenges in obtaining regulatory approval. While human trials could take decades to succeed, some companies are showing a willingness to pour massive investments into this field.

Meanwhile, a company named Loyal has claimed to have developed a new drug capable of slowing the biological aging of dogs. This medication shows the potential to extend the lives of pet dogs by several years. The drug developed by the company is a chewable tablet named LOY-002, specifically designed for dogs over 10 years old and of medium to large breeds. 

This drug targets a hormone in the dog's body called IGF-1, which regulates growth and metabolism. However, high levels of this hormone as the dog ages can accelerate the cellular aging process. According to the company, the drug helps slow down the biological clock of dogs by reducing the effects of IGF-1, which can improve the quality of life in their senior years.

The drug has already received initial safety approval from the US FDA, signaling that it has passed a significant milestone toward market entry. Now, a final large-scale clinical trial to confirm its efficacy remains. If the trial is successful, the company aims to bring this drug to market by 2027.